twenty-one patients with advanced , measurable , renal cell carcinoma ( rcc ) were administered recombinant interferon alfa-2a ( rifn-alpha 2a ) ( roferon-a ; roche laboratories , nutley , nj ) intramuscularly beginning at 3 x 10 ( 6 ) units and escalating to 36 x 10 ( 6 ) units , 5 d/wk for a total induction period of 14 weeks .
C0007134
renal cell carcinoma
C0021734
recombinant interferon alfa-2a